Dr. Dustin Deming leads new collaboration to identify precision colorectal cancer treatments
A partnership between UW–Madison and Immuto Scientific
Dustin Deming, MD, professor, Hematology, Medical Oncology and Palliative Care, is leading a new research partnership between the University of Wisconsin–Madison (UW–Madison) and a biotech company named Immuto Scientific, to identify safer, more precise treatments for colorectal cancer.
“Through this collaboration with Immuto Scientific, we aim to identify new molecular targets that may ultimately improve treatment options for patients.”
Dr. Deming
The collaboration will leverage Immuto Scientific’s structural surfaceomics platform, an AI-enabled analytics technology that maps the three-dimensional structure of proteins on the surface of cancer cells.
This mapping can reveal undiscovered surface protein conformations—or SPCs—which may in turn offer brand‑new targets for future cancer drugs.
"Our collection of patient-derived colorectal cancer organoids enables exploration of tumor biology and therapeutic vulnerabilities in ways that traditional models cannot,” says Dr. Deming, who is an expert in colorectal cancer and a member of the UW Carbone Cancer Center. “Through this collaboration with Immuto Scientific, we aim to identify new molecular targets that may ultimately improve treatment options for patients.”
The new collaboration will also provide Immuto Scientific with access to unique, patient-derived organoid models representing microsatellite-stable colorectal cancer.
Read the full story from the UW School of Medicine and Public Health.